Introduction
Currently the management of heart failure in general practice will vary depending on general practitioner's (GP) experience, skills, knowledge and the availability services locally.
To reduce inequality and promote a standardised service based on quality and prevention the South Central cardiovascular network has outlined a primary care pathway for patients with suspected or confirmed heart failure based on national guidelines and local expertise. This level of service is expected for all appropriate patients to ensure optimum management of the condition is achieved within General Medical Services (GMS).
The GP has the responsibility to coordinate the care throughout the pathway ensuring timely access to diagnostic and management interventions following the initial presentation of symptoms. Heart failure creates a significant economic burden and more importantly compromising patients' quality of life 1 .
The future of heart failure services is dependent on GP's commissioning reliable high-quality healthcare and evidence suggests considerable savings can be made by ensuring patients have access to early diagnosis, appropriate prescribing and support with compliance 1 . It is estimated heart failure costs the NHS around 2% of the budget with 70% of the cost incurred due to hospital admissions 2 , however commissioning a service which incorporates evidence based interventions may reduce the financial burden by 24%, and the annual number of deaths by 1,300 1 .
Definition of Heart Failure
Heart failure is a complex clinical syndrome of symptoms and signs that suggest the efficiency of the heart as a pump is impaired caused by structural or functional abnormalities of the heart. Some patients have heart failure due to left ventricular systolic dysfunction (LVSD) which is associated with a reduced left ventricular ejection fraction. Others have heart failure with a preserved ejection fraction (HFPEF). Most of the evidence on treatment is for heart failure due to LVSD. The most common cause of heart failure in the UK is coronary artery disease, and many patients have had a myocardial infarction in the past' 3 .
Incidence, Prevalence and Activity
The incidence of heart failure is estimated between 1 and 5 cases per 1000 population per annum. This increases steeply with age to as high as 40 per 1000 per annum in those aged over 76 years. Therefore, as many as 63,000 new cases of heart failure are diagnosed each year in the UK (34,000 in men and 29,000 in women). The average GP will see 2 or 3 new patients with heart failure every year based on an incidence of approximately 1 case per 1000 population per year.
It is estimated that heart failure affects 1-2% of the population, which means that between 600,000 and 900,000 people in the UK have the condition. Therefore, a GP with a list of 2000 patients is likely to be caring for 20-30 patients with heart failure. Patients have frequent contact with primary care, requiring on average 11-13 contacts per year with the GP or other members of the primary care team. By contrast, drug costs in heart failure account for a very small proportion of the total cost of care, around 9% 4 . There is considerable variation in the prevalence of heart failure by primary care trusts in South Central (0.1% to more than 1.6%) and that patients are potentially under-diagnosed and, therefore, not receiving optimal levels of care.
National Drivers

National Institute for Health and Clinical Excellence (NICE)
The NICE clinical guideline on chronic heart failure published in August 2010 best practice advice that takes into consideration patients' needs and preferences by bringing together new high-quality evidence from randomised controlled trials in diagnosis, treatment, rehabilitation and monitoring. The guideline recommends that care should be appropriately commissioned and delivered by a multidisciplinary team with an integrated approach across the healthcare community to reduce recurrent hospital stays, improve clinical outcomes by prolonging and improving quality of life and reducing inequalities.
Care Quality Commission
A review of heart failure services in 2007 5 provides the following recommendations:
 all patients with suspected heart failure are identified and offered effective investigations to confirm or refute a diagnosis;  all patients with a confirmed diagnosis have access to specialist staff, services and the full range of recommended treatments to optimise their clinical condition and quality of life;  audit the delivery of care to ensure the best outcomes for patients and to demonstrate the cost benefits of delivering services  commissioners should review their local recorded prevalence for heart failure against national predicted rates;  commissioners should put arrangements in place to ensure that all patients with suspected heart failure have rapid access to the key defining investigations to confirm or refute the diagnosis;  commissioners should work together with service providers to ensure that all patients with confirmed heart failure have access to the specialist advice and services they require;  commissioners should specify and commission cost effective models of multidisciplinary service delivery seamlessly encompassing both primary and secondary care The Pathway
Diagnosis
History and examination findings
The history has to be interpreted in the context of the past medical history. Breathlessness in patients with a history of myocardial infarction is commonly associated with the onset of heart failure.
In many patients with moderate-to-severe LVSD or early symptoms of heart failure, there are few abnormal physical findings. The following is a guide to assist in the recognition of patients who may have heart failure (HF):
Abnormal physical findings in heart failure may include:
 Tachycardia, irregular pulse  Elevated jugular venous pressure or positive hepato-jugular reflux  A third heart sound  Laterally displaced apical impulse  Pulmonary rales that do not clear with coughing A pathological third heart is a highly specific clinical signs but is often clinically difficult to identify. Rales and/or a displaced apical impulse are present in about a third of patients. Jugular venous distension and peripheral oedema are important physical findings however their absence does not exclude heart failure. Peripheral oedema is common but a rather non-specific finding and other causes (e .g. varicose insufficiency and immobility in the elderly) need to be considered. 
Predisposing factors and differential diagnosis
There are a number of predisposing factors that are common in patients with heart failure. These include:
There are also a number of other conditions that may present with similar clinical features:
Diagnostic Pathway
Given the uncertainties that are intrinsic to a clear diagnosis of heart failure on physical examination alone, and the outcome for patients left undiagnosed it is important that a defined pathway should be followed.
The pathway includes the use of electrocardiography (ECG) and serum natriuretic peptide (SNP) testing (B-Type Natriuretic Peptide (BNP) or N-terminal pro-B-type natriuretic peptide (NTProBNP)) as essential diagnostic tools to assist the GP. Performing an ECG will reduce the indiscriminate use of BNP testing which increases cost effectiveness and ensures good clinical practice 6 . Mandatory inclusion of ECG in the pathway is a variance form the NICE guidelines but consensus from clinical leads in South Central suggest this is an important diagnostic tool which should not be disregarded. The following flowchart outlines the agreed criteria for use within the Oxfordshire PCG. They refer to all patients presenting with symptoms in which heart failure is suspected. Referral forms on (EMISweb) can be used for both GPwSI referrals and secondary care referrals using the same e mail single point of access -heartfailure.oxford@nhs.net If symptoms are sufficiently severe they warrant treatment while waiting for echocardiography and specialist assessment.
Consider prescribing a loop diuretic 7 :
 Furosemide is the preferred choice of diuretic -usually given once daily in the morning but may be given twice daily for additional diuresis, titrate the dose to control symptoms. Bumetanide may be more effective in patients who are severely oedematous.
Specific monitoring recommendations for patients prescribed a loop diuretic:
 measure renal function and serum electrolytes prior to treatment initiation and check 1-2 weeks after treatment commencement and after each change in dose  earlier monitoring (within 5-7 days) may be required for patients with:
-existing renal impairment taking a combination of a loop diuretic plus an angiotensinconverting enzyme (ACE) inhibitor, angiotensin-II receptor antagonist, aldosterone antagonist and thiazide Secondary care specialist advice recommended:
 symptoms are severe and do not respond to diuretics  patient is pregnant  patient has angina, atrial fibrillation or flutter, or another symptomatic arrhythmia  viral, alcoholic, or toxic cardiomyopathy is suspected  Associated valvular heart disease  Patients unable to tolerate ACE inhibition or AII receptor antagonists due to renal impairment or symptomatic hypotension
Management following diagnosis
Some patients have heart failure due to left ventricular systolic dysfunction (LVSD) which is associated with a reduced left ventricular ejection fraction. Others have heart failure with a preserved ejection fraction (HFPEF, also known as Diastolic Heart Failure). The majority of evidence on treatment is for heart failure due to LVSD; therefore for those with HFPEF management should be in consultation with a cardiologist. The following recommendations are based around patients with LVSD. There are a number of both pharmacological and non-pharmacological strategies that can be utilised in the management of heart failure. They can be delivered in predominantly in primary care with support from secondary care cardiology services. The main elements of care are outlined in the algorithm below:
Left ventricular systolic dysfunction (LVSD), also known as
Key Prescribing Points
 All patients with LVSD should be considered for ACE inhibitor and beta-blocker therapy. ACEI is usually started first.
 Aim for the target dose of ACEI and beta-blocker. Some is better than none though, and a little of each is better than lots of one and none of the other.
 Cough is common in heart failure. ACEI cause cough in some patients. The effect of ACEI on survival is more certain than that of angiotensin receptor blockers. Do not rule out ACE inhibitors until absolutely certain that the drug is causing the cough.
 Beta-blockers are often tolerated & not contra indicated in COPD, peripheral vascular disease or diabetes mellitus. Wheeze may be present periodically in heart failure and COPD. Do not stop the beta-blocker unless you are absolutely certain it is causing bronchospasm.
 If there are symptoms of postural hypotension from taking all the medication in the morning, consider giving ACEI in the evening.  For patients intolerant of ACE due to cough, consider Angiotensin II receptor antagonist; candesartan is preferred choice, target dose 32mg  Monitor serum urea, creatinine & electrolytes at initiation and each dose increment; see section 6.5 below for advice on results.  Beta-blocker; initiate even if rendered asymptomatic by ACE +/-diuretic  Start low and titrate upwards slowly (see appendix 2 for detail)  1 st line choices & target doses; Bisoprolol 10mg od or carvedilol 25mg bd -if previously on a non-selective beta-blocker, switch to one licensed for heart failure  Assess heart rate, blood pressure and clinical status after each titration  Other drugs to consider Digoxin is recommended for:  Worsening or severe heart failure due to LVSD despite ACE-I, beta-blocker and diuretic therapy  Patients in AF with heart failure; heart rate control best achieved with a beta-blocker but digoxin may be added if rate control is inadequate or beta-blocker not tolerated Ivabridine: For patients in sinus rhythm intolerant of beta blockade or with a heart rate >75 on beta blockade. Cardiologist review required.
Calcium Channel blockers
Amlodipine could be considered for the treatment of co-morbid hypertension / angina in patients with heart failure but verapamil or short acting dihydropyridine agents should be avoided
Aspirin & Simvastatin
Aspirin (75mg od) and simvastatin (40mg od) should be prescribed for patients with the combination of heart failure and atherosclerotic arterial disease. Evidence suggests HFSNs play a vital role in the management of people with heart failure caused by LVSD. The recommended number of full time nurses is 1 per 100,000 population for patients with heart failure and systolic dysfunction alone*. 9 Local data suggests each nurse has the ability to manage an average of 70 referrals per year however this may vary according to local protocols. This specialist support has the potential to save over £1800 per patient mainly from avoided acute admissions due to early intervention strategies. The nurses have the ability to manage patients autonomously and free up GP time by recognising the symptoms of deterioration, titrating medication and providing educational programmes based around self-management and lifestyle modification.
This aspect of the service is increasingly important as the diagnostic pathway is implemented to ensure adequate support is available for newly diagnosed patients. Without HFSNs any savings from avoided admissions in the diagnostic stage may be lost. Quality support for patients and their families is paramount following diagnosis as it is estimated over 40% of patients will not survive for more than 18 months 10 .
Community HFSN should have an agreed competency framework and should have an integrated time commitment and infrastructure with secondary care for education, training and continued professional development to ensure and maintain quality standards.
At present it is recommended only patients with LVSD are referred to HFSN services as other types of heart failure (e.g. HFPEF) require management in consultation with a cardiologist. However as evidence emerges on the management of these patients there is no reason why a competent HFSN could not manage a range of patients with appropriate training. The ratio of nurse per patient population would need to be reviewed to allow for an increased capacity to take on new groups of patients.
*Diastolic heart failure which accounts for 50% of heart failure presentations is not included in this calculation. 
Cardiac Resynchronisation
Cardiac resynchronisation therapy has been associated with a reduction in all-cause mortality by 28% and new hospitalisations for worsening heart failure by 37% 11 .
There are two types of implantable device for congestive heart failure 12 :
 A cardiac resynchronisation therapy with a pacing device (CRT -P)  A cardiac resynchronisation therapy with a defibrillator device (CRT-D)
NICE recommend CRT-P as a possible treatment where these circumstances apply:
 For people with moderate to severe heart failure affecting daily life (NYHA class II -IV)  Regular heart beat but ECG show the electrical system is not working properly (are in sinus rhythm either with a QRS duration of 120 ms or longer estimated by standard. *  Left ventricular ejection fraction is 35% or less  They are receiving optimal pharmacological therapy NICE recommend CRT-D as a possible treatment where these circumstances apply:
 All patients with an ejection fraction <30% where prognostic intervention is appropriate.  The person is also suitable for an implantable cardioverter defibrillator * Evidence published since the NICE review suggests that patients with atrial fibrillation and ejection fraction of less than 35% and prolonged QRS duration may also benefit.
Transplantation
Management of advanced Heart Failure with transplantation should be considered on an individual case basis. • Double dose at not less than 2 weekly intervals • Aim for target dose (see above) or, failing that, the highest tolerated dose • Remember some beta-blocker is better than no beta-blocker • Monitor heart rate, blood pressure, clinical status (symptoms, signs, especially signs of congestion, body weight) • Check blood electrolytes, urea and creatinine 1-2 weeks after initiation and 1-2 weeks after final dose titration • When to down-titrate/stop up-titration, see 'Problem solving' Advice to patient • Explain expected benefits • Emphasise that treatment given as much to prevent worsening of heart failure as to improve symptoms; beta-blockers also increase survival • If symptomatic improvement occurs, this may develop slowly (3-6 months or longer) • Temporary symptomatic deterioration may occur (estimated 20-30% of cases) during initiation/up-titration phase • Advise patient to report deterioration (see 'Problem solving') and that deterioration (tiredness, fatigue, breathlessness) can usually be easily managed by adjustment of other medication; patients should be advised not to stop beta-blocker therapy without consulting their physician • Patients should be encouraged to weigh themselves daily (after waking, before dressing, after voiding, before eating) and to consult their doctor if they have persistent weight gain
Appendix 1: Practical recommendations on the use of ACE
Problem solving
Worsening symptoms/signs (e.g. increasing dyspnoea, fatigue, oedema, weight gain) • If increasing congestion, double dose of diuretic and/or halve dose of betablocker (if increasing diuretic does not work) • If marked fatigue (and/or bradycardia, see below) halve dose of beta-blocker (rarely necessary) • Review patient in 1-2 weeks; if not improved seek specialist advice • If serious deterioration, halve dose of beta-blocker or stop this treatment (rarely necessary); seek specialist advice Low heart rate • If < 50 beats/min and worsening symptoms -halve dose beta-blocker or, if severe deterioration, stop beta-blocker (rarely necessary)
